Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan; â¡Chibune ... Published online ahead of print. ..... sonography at baseline.
Cinacalcet Effectively Reduces Parathyroid Hormone Secretion and Gland Volume Regardless of Pretreatment Gland Size in Patients with Secondary Hyperparathyroidism Hirotaka Komaba,*† Shohei Nakanishi,‡ Akira Fujimori,§ Motoko Tanaka,储 Jeongsoo Shin,¶ Koji Shibuya,** Masato Nishioka,**†† Hirohito Hasegawa,‡‡ Takeshi Kurosawa,§§ and Masafumi Fukagawa*† *Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Japan; †Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan; ‡Chibune Kidney and Dialysis Clinic, Osaka, Japan; §Division of Blood Purification and Kidney Center, Konan Hospital, Kobe, Japan; 储Department of Nephrology, Akebono Clinic, Kumamoto, Japan; ¶Motomachi HD Clinic, Kobe, Japan; **Sumiyoshigawa Hospital, Kobe, Japan; ††Sumiyoshigawa Clinic, Kobe, Japan; ‡‡Department of Nephrology and Blood Purification Center, Rokko Island Hospital, Kobe, Japan; and §§Sumiyoshi Clinic Hospital, Mito, Japan Background and objectives: Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether parathyroid gland size predicts response to therapy and whether cinacalcet is capable of inducing a reduction in parathyroid volume. Design, setting, participants, & measurements: This 52-week, multicenter, open-label study enrolled hemodialysis patients with moderate to severe secondary hyperparathyroidism (intact PTH >300 pg/ml). Doses of cinacalcet were adjusted between 25 and 100 mg to achieve intact PTH
